Evidence map›Paper›PMID 27882158›Full record

ArticleExperimental and therapeutic medicine2016

Functional characterization of human umbilical cord-derived mesenchymal stem cells for treatment of systolic heart failure.

Zhihua Fang, Xiaoguang Yin, Jianzhong Wang, Na Tian, Qiang Ao, Yongquan Gu, Ying Liu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. The application of umbilical cord-derived MSCs in cardiovascular diseases.Journal of cellular and molecular medicine · 2021
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhihua FangDepartment of Hematology, Siping Hospital of China Medical University, Siping, Jilin 136000, P.R. China; Jilin Tuhua Bioengineering Company Limited, Siping, Jilin 136000, P.R. China.
Xiaoguang YinJilin Tuhua Bioengineering Company Limited, Siping, Jilin 136000, P.R. China.
Jianzhong WangDepartment of Hematology, Siping Hospital of China Medical University, Siping, Jilin 136000, P.R. China.
Na TianJilin Tuhua Bioengineering Company Limited, Siping, Jilin 136000, P.R. China.
Qiang AoDepartment of Tissue Engineering, China Medical University, Shenyang, Liaoning 110122, P.R. China.
Yongquan GuDepartment of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China.
Ying LiuJilin Tuhua Bioengineering Company Limited, Siping, Jilin 136000, P.R. China; The Key Tissue Engineering of Jilin Province, Siping, Jilin 136000, P.R. China.
China Medical University · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congestive heart failure (HF) is a leading cause of morbidity and mortality worldwide. Although advances in medical therapy, mechanical support and heart transplantation have been made, almost half of all patients with HF succumb to the disease within five years of the initial diagnosis. Therefore, treatment methods need to be identified to restore the structure and function of cardiac muscle. Three patients with HF caused by ischemic cardiomyopathy received human umbilical cord-derived mesenchymal stem cell (HUC-MSC) intravenous infusion were included in the present study. Two patients demonstrated a 65.1% increase in left ventricular ejection fraction (LVEF) at the end of 3 months, which was maintained increasing 47.8% at the end of 12 months post-HUC-MSC intravenous infusion. LVEF of patient 1 decreased slowly in the observation period. This LVEF improvement was associated with significant improvements in the clinical parameters of the New York Heart Association class, and six-minute walk test in the coupled time. The third patient showed significant improvement in the six-minute walk test at the end of 12 months, while the other parameters did not change obviously. There were no severe adverse events during and post-HUC-MSC transplantation. During follow-up, no other immunosuppressive drugs were used. In conclusion, HUC-MSC therapy is a reasonable salvage treatment in HF. Future large-scale randomized clinical trials are likely to be designed to elucidate the efficacy of the HUC-MSC transplantation therapy on HF.

Indexed as

efficacyheart failurehuman umbilical cord-derived mesenchymal stem cellsintravenous infusionsafety

Identifiers

PMID27882158
PMCPMC5103788
OpenAlexW2526469426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.